Executive Vice President, Ventures and Chief Experience and Technology Officer · CVS HEALTH Corp (CVS)

Tilak Mandadi

A named executive officer of CVS HEALTH in every fiscal year CompBrief holds from FY2023 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$10,977,716

FY2024: $11,361,343

Compensation figures as of the proxy filed April 3, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-09-24.

Tilak Mandadi compensation by year

CVS HEALTH Summary Compensation Table · all 3 fiscal years held
In US dollars, as CVS HEALTH reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024FY2025
Salary$1,000,000$1,000,000$1,000,000
Bonus$0$0$0
Stock awards$4,874,990$8,199,843$5,599,965
Option awards$1,624,993$1,299,989$1,399,996
Non-equity incentive$1,246,000$583,000$2,561,000
Pension and deferred compensation$0$0$0
All other$135,862$278,511$416,755
Total$8,881,845$11,361,343$10,977,716

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CVS HEALTH Corp DEF 14A filed April 3, 2026, accession 0001308179-26-000201, and prior-year filings. Open the filing on EDGAR.

$8.9M
$11.4M
$11.0M
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
PSU52,757$4,186,796—
PSU50,893$4,038,868—
RSU33,417$2,651,973—
RSU30,732$2,438,892—
RSU20,594$1,634,340—
RSU12,255$972,557—
Option87,336—$67.98
Option50,940—$79.56
Option48,248—$74.31

Per the Outstanding Equity Awards at Fiscal Year-End table in CVS HEALTH Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2025 proxy (filed April 3, 2026)
current to 2026-09-24 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-08Sale—69,551$89.5810,133

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments CVS HEALTH discloses, by trigger · FY2025
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Death$0$20,819,458$0$20,819,458
Involuntary termination without cause$1,500,000$12,391,515$14,996$13,906,511
Retirement$0$0$0$0
Involuntary for cause$0$-20,819,458$0$-20,819,458
Change in control and involuntary termination$1,500,000$20,819,458$14,996$26,084,454

Per the Potential Payments Upon Termination or Change in Control table in CVS HEALTH Corp's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.

CVS HEALTH’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
J. David JoynerPresident and Chief Executive Officer$21,214,084
Prem ShahExecutive Vice President and Group President$13,379,210
Steven NelsonExecutive Vice President and President, Aetna$11,587,110
Tilak Mandadi · this pageExecutive Vice President, Ventures and Chief Experience and Technology Officer$10,977,716
Brian NewmanExecutive Vice President and Chief Financial Officer$9,420,508
Thomas CowheyFormer Executive Vice President and Chief Financial Officer$6,715,138

The full CVS HEALTH compensation record

free company brief

This page is one person within CVS HEALTH's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CVS HEALTH's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CVS HEALTH's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy